Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insmed (INSM) Q2 2025 10-Q highlights
- Net sales up 19% to $107.4 m; six-month sales rose 21% to $200.2 m, driven by ARIKAYCE growth in Japan (+45%) and continued U.S. demand.
- Spending accelerated. R&D jumped 21% YoY to $177.2 m and SG&A 45% to $154.8 m. Total operating expenses were $420.3 m, lifting the operating loss to $312.9 m (-8% YoY).
- Wider bottom-line loss. Net loss reached $321.7 m (-$1.70/sh) versus $300.6 m (-$1.94/sh) a year ago; six-month loss deepened to $578.3 m.
- Balance-sheet reset. All $575 m 0.75% 2028 converts were converted/redemed in Q2, cutting long-term debt nearly 51% to $538.5 m (term loans only) and adding 17.9 m shares. Shareholders’ equity rose to $1.25 b from $0.29 b.
- Liquidity bolstered. Cash & cash equivalents soared to $1.28 b (vs. $0.56 b YE-24) after $823.5 m equity raise and $146 m draw of Tranche B term loan; total liquidity (cash+securities) $1.86 b.
- Cash burn rising. Operating cash outflow was -$468 m for H1 vs. -$307 m prior-year.
- Contingent consideration liability climbed to $246 m (+46% YTD) on Motus/AlgaeneX milestones.
Company says cash on hand funds operations for ≥12 months while it advances brensocatib Phase 3, TPIP, INS1201 and expands ARIKAYCE indications. No forward guidance provided.
Insmed Inc. (INSM) – Form 4 insider transaction dated 07/15/2025
Chairman & CEO William Lewis, acting through the Katie Procter Dynasty Trust, exercised 6,830 stock options at an exercise price of $10.85 and immediately sold the same 6,830 shares under a Rule 10b5-1 trading plan adopted on 09/12/2024. The shares were disposed of in three tranches at weighted-average prices of $101.71, $102.66 and $103.32, generating roughly $0.7 million in gross proceeds.
Following the transactions, Lewis’ total beneficial ownership equals 588,335 common shares (303,911 direct; 233,924 via the Dynasty Trust; 50,500 via the Family Legacy Trust). The option exercise did not change his overall share count, but the sales reduced the Dynasty Trust’s holdings by 2.8%. No derivative positions were opened or closed other than the exercised option, which now leaves 13,695 options outstanding for the Trust.
The sale size is modest relative to Lewis’ remaining stake and was pre-scheduled, limiting signaling value. Nevertheless, investors often view insider disposals, especially near 52-week highs (INSM traded >$100), as a potential sentiment check.
Insmed Inc. (INSM) Form 4 filing discloses two open-market sales by Chief Legal Officer Michael A. Smith.
- 07/11/2025: 748 common shares sold at $96.41 to satisfy tax-withholding on RSU vesting.
- 07/15/2025: 933 common shares sold at a $102.51 weighted-average price under a pre-arranged Rule 10b5-1 trading plan adopted 02/27/2025.
- Total shares disposed: 1,681, representing roughly 2.5 % of his pre-sale direct holdings.
- Post-sale direct ownership: 66,394 shares, including 357 acquired via the 2018 ESPP.
No derivative transactions were reported. Sales appear routine and transparent, suggesting limited immediate valuation impact for investors.